Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2014 Nov;10(6):799-807.e2.
doi: 10.1016/j.jalz.2014.05.1749. Epub 2014 Jul 8.

Plasma proteins predict conversion to dementia from prodromal disease

Abdul Hye  1 , Joanna Riddoch-Contreras  1 , Alison L Baird  1 , Nicholas J Ashton  1 , Chantal Bazenet  1 , Rufina Leung  1 , Eric Westman  2 , Andrew Simmons  1 , Richard Dobson  1 , Martina Sattlecker  1 , Michelle Lupton  3 , Katie Lunnon  4 , Aoife Keohane  1 , Malcolm Ward  5 , Ian Pike  5 , Hans Dieter Zucht  5 , Danielle Pepin  6 , Wei Zheng  6 , Alan Tunnicliffe  6 , Jill Richardson  7 , Serge Gauthier  8 , Hilkka Soininen  9 , Iwona Kłoszewska  10 , Patrizia Mecocci  11 , Magda Tsolaki  12 , Bruno Vellas  13 , Simon Lovestone  14
Affiliations
Multicenter Study

Plasma proteins predict conversion to dementia from prodromal disease

Abdul Hye et al. Alzheimers Dement. 2014 Nov.

Abstract

Background: The study aimed to validate previously discovered plasma biomarkers associated with AD, using a design based on imaging measures as surrogate for disease severity and assess their prognostic value in predicting conversion to dementia.

Methods: Three multicenter cohorts of cognitively healthy elderly, mild cognitive impairment (MCI), and AD participants with standardized clinical assessments and structural neuroimaging measures were used. Twenty-six candidate proteins were quantified in 1148 subjects using multiplex (xMAP) assays.

Results: Sixteen proteins correlated with disease severity and cognitive decline. Strongest associations were in the MCI group with a panel of 10 proteins predicting progression to AD (accuracy 87%, sensitivity 85%, and specificity 88%).

Conclusions: We have identified 10 plasma proteins strongly associated with disease severity and disease progression. Such markers may be useful for patient selection for clinical trials and assessment of patients with predisease subjective memory complaints.

Keywords: Alzheimer's disease; Biomarker; Mild cognitive impairment; Pathology; Plasma; Prediction and magnetic resonance imaging.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Feature selection workflow used to select the best attributes for mild cognitive impairment converter (MCIc) classification.
Fig. 2
Fig. 2
Receiver operating characteristic (ROC) curves obtained for the test set for (A) three models (proteins only, proteins + apolipoprotein E [APOE], and APOE only) from the full mild cognitive impairment, converter and nonconverter (MCIc and MCInc) data sets and (B) for the test set for three models (proteins only, proteins + APOE + magnetic resonance imaging [MRI], and MRI only) in the subset with protein plus MRI imaging data.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L. Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006;129:3042–3050. - PubMed
    1. Cutler P., Akuffo E.L., Bodnar W.M., Briggs D.M., Davis J.B., Debouck C.M. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin Appl. 2008;2:467–477. - PubMed
    1. Akuffo E.L., Davis J.B., Fox S.M., Gloger I.S., Hosford D., Kinsey E.E. The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers. 2008;13:618–636. - PubMed
    1. Kimura M., Asada T., Uno M., Machida N., Kasuya K., Taniguchi Y. Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. Neurosci Lett. 1999;273:137–139. - PubMed
    1. Kessler H., Pajonk F.G., Meisser P., Schneider-Axmann T., Hoffmann K.H., Supprian T. Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease. J Neural Transm. 2006;113:1763–1769. - PubMed

Publication types